Citriodiol® and Impetigo

• Status: Unknown status
• Trial end date: 2013-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to investigate the efficacy and safety of topical p-menthane-3,8-diol (PMD)-rich Corymbia Citriodora oil (Citriodiol®) in children with impetigo. Citriodiol® is already known to be effective as an insect repellent and is safe in its topical application. The investigators have also found in our laboratory that it is bactericidal against Staphylococcus aureus, the bacteria responsible for causing impetigo. Parents are always searching for a natural alternative to antibiotics (the current gold standard treatment for impetigo), and the investigators believe Citriodiol® could provide this possible alternative.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Royal North Shore Hospital
• Treatments: Menthol; Terpin

Criteria

Inclusion Criteria:

• age between 12 months and 12 years

• dermatologist-confirmed impetigo

• written informed consent provided by parents

Exclusion Criteria:

• impetigo requiring oral/systemic therapy

• diagnosis of another form of staphylococcal or streptococcal disease (eg, cellulitis, erysipelas, abscess)

• serious local infection (eg, cellulitis, abscess, wound infection) or systemic infection

• oral or topical antibiotics

• known allergy to topical insect repellents

• patients receiving systemic corticosteroids, immunosuppressive agents, radiation therapy, chemotherapy within 1 month prior to entry into study

• history of any clinically significant or poorly controlled cardiac, haematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, psychiatric, and/or other major disease as determined by the investigator

• current enrollment in any other trial of an investigational drug within 30 days prior to study drug administration

• other unspecified reasons, in the opinion of the investigator that makes the patient unsuitable for enrollment.